|
1
|
Papatheodoridis G, Buti M, Cornberg M,
Janssen H, Mutimer D, Pol S and Raimondo G: EASL clinical practice
guidelines: Management of chronic hepatitis B virus infection. J
Hepatol. 57:167–185. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Raffetti E, Fattovich G and Donato F:
Incidence of hepatocellular carcinoma in untreated subjects with
chronic hepatitis B: A systematic review and meta-analysis. Liver
Int. 36:1239–1251. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lampertico P, Agarwal K, Berg T, Buti M,
Janssen HLA, Papatheodoridis G, Zoulim F and Tacke F: EASL 2017
clinical practice guidelines on the management of hepatitis B virus
infection. J Hepatol. 67:370–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Si J, Yu C, Guo Y, Bian Z, Qin C, Yang L,
Chen Y, Yin L, Li H, Lan J, et al: Chronic hepatitis B virus
infection and risk of chronic kidney disease: A population-based
prospective cohort study of 0.5 million Chinese adults. BMC Med.
16(93)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rouillard S and Lane NE: Hepatic
osteodystrophy. Hepatology. 33:301–307. 2001.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ehnert S, Aspera-Werz RH, Ruoß M, Dooley
S, Hengstler JG, Nadalin S, Relja B, Badke A and Nussler AK:
Hepatic osteodystrophy-molecular mechanisms proposed to favor its
development. Int J Mol Sci. 20(2555)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Leslie WD, Bernstein CN and Leboff MS:
American Gastroenterological Association Clinical Practice
Commitee. AGA technical review on osteoporosis in hepatic
disorders. Gastroenterology. 125:941–966. 2003.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen CH, Lin CL and Kao CH: Association
between chronic hepatitis B virus infection and risk of
osteoporosis: A nationwide population-based study. Medicine
(Baltimore). 94(e2276)2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Baeg MK, Yoon SK, Ko SH, Han KD, Choi HJ,
Bae SH, Choi JY and Choi MG: Males seropositive for hepatitis B
surface antigen are at risk of lower bone mineral density: The
2008-2010 Korea national health and nutrition examination surveys.
Hepatol Int. 10:470–477. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shimizu T, Arita K, Murota E, Hiratsuka S,
Fujita R, Ishizu H, Asano T, Takahashi D, Takahata M and Iwasaki N:
Effects after starting or switching from bisphosphonate to
romosozumab or denosumab in Japanese postmenopausal patients. J
Bone Miner Metab. 39:868–875. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Miller PD, Hochberg MC, Wehren LE, Ross PD
and Wasnich RD: How useful are measures of BMD and bone turnover?
Curr Med Res Opin. 21:545–554. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Agarwal K, Brunetto M, Seto WK, Lim YS,
Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, et al: 96
weeks treatment of tenofovir alafenamide vs tenofovir disoproxil
fumarate for hepatitis B virus infection. J Hepatol. 68:672–681.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Seto WK, Asahina Y, Brown TT, Peng CY,
Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma
T, et al: Improved bone safety of tenofovir alafenamide compared to
tenofovir disoproxil fumarate over 2 years in patients with chronic
HBV infection. Clin Gastroenterol Hepatol, Jun 20, 2018 (Online
ahead of print).
|
|
14
|
Chan HL, Fung S, Seto WK, Chuang WL, Chen
CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, et al:
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the
treatment of HBeAg-positive chronic hepatitis B virus infection: A
randomised, double-blind, phase 3, non-inferiority trial. Lancet
Gastroenterol Hepatol. 1:185–195. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ogawa E, Nomura H, Nakamuta M, Furusyo N,
Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, et al:
Tenofovir alafenamide after switching from entecavir or
nucleos(t)ide combination therapy for patients with chronic
hepatitis B. Liver Int. 40:1578–1589. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Notsumata K, Nomura Y, Tanaka A, Ueda T,
Sanada T, Watanabe H and Toya D: Early changes in tubular
dysfunction markers and phosphorus metabolism regulators as a
result of switching from entecavir to tenofovir alafenamide
fumarate nucleoside analog therapy for chronic hepatitis B
patients. Hepatol Res. 50:402–404. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hagiwara S, Nishida N, Ida H, Ueshima K,
Minami Y, Takita M, Komeda Y and Kudo M: Switching from entecavir
to tenofovir alafenamide versus maintaining entecavir for chronic
hepatitis B. J Med Virol. 91:18040–1810. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Uchida Y, Nakao M, Tsuji S, Uemura H,
Kouyama JI, Naiki K, Motoya D, Sugawara K, Nakayama N, Imai Y, et
al: Significance of switching of the nucleos(t)ide analog used to
treat Japanese patients with chronic hepatitis B virus infection
from entecavir to tenofovir alafenamide fumarate. J Med Virol.
92:329–338. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tamaki N, Kurosaki M, Nakanishi H, Itakura
J, Inada K, Kirino S, Kirino S, Yamashita K, Osawa L, Sekiguchi S,
et al: Comparison of medication adherence and satisfaction between
entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
J Med Virol. 92:1355–1358. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shephard DA: The 1975 declaration of
Helsinki and consent. Can Med Assoc J. 115:1191–1192.
1976.PubMed/NCBI
|
|
21
|
Assessment of fracture risk and its
application to screening for postmenopausal osteoporosis. Report of
a WHO study group. World Health Organ Tech Rep Ser. 843:1–129.
1994.PubMed/NCBI
|
|
22
|
Matsuo S, Imai E, Horio M, Yasuda Y,
Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H and Hishida A:
Collaborators developing the Japanese equation for estimated GFR.
Revised equations for estimated GFR from serum creatinine in Japan.
Am J Kidney Dis. 53:982–992. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kashani KB, Frazee EN, Kukrálová L,
Sarvottam K, Herasevich V, Young PM, Kashyap R and Lieske JC:
Evaluating muscle mass by using markers of kidney function:
Development of the sarcopenia index. Crit Care Med. 45:e23–e29.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kim SW, Jung HW, Kim CH, Kim K, Chin HJ
and Lee H: A new equation to estimate muscle mass from creatinine
and cystatin C. PLoS One. 11(e0148495)2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Spirlandeli AL, Dick-de-paula I, Zamarioli
A, Jorgetti V, Ramalho LNZ, Nogueira-Barbosa MH, Volpon JB, Jordão
AA, Cunha FQ, Fukada SY and de Paula FJA: Hepatic osteodystrophy:
The mechanism of bone loss in hepatocellular disease and the
effects of pamidronate treatment. Clinics (Sao Paulo). 72:231–237.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lv Y, Wang G, Xu W, Tao P, Lv X and Wang
Y: Tartrate-resistant acid phosphatase 5b is a marker of osteoclast
number and volume in RAW 264.7 cells treated with
receptor-activated nuclear κB ligand. Exp Ther Med. 9:143–146.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ivaska KK, Gerdhem P, Väänänen HK, Akesson
K and Obrant KJ: Bone turnover markers and prediction of fracture:
A prospective follow-up study of 1040 elderly women for a mean of 9
years. J Bone Miner Res. 25:393–403. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kasai H, Mori Y, Ose A, Shiraki M and
Tanigawara Y: Prediction of fracture risk from early-stage bone
markers in patients with osteoporosis treated with once-yearly
administered zoledronic acid. J Clin Pharmacol. 61:606–613.
2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wei MT, Le AK, Chang MS, Hsu H, Nguyen P,
Zhang JQ, Wong C, Wong C, Cheung R and Nguyen MH: Antiviral therapy
and the development of osteopenia/osteoporosis among Asians with
chronic hepatitis B. J Med Virol. 91:1288–1294. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fung J, Seto W, Lai C and Yuen M:
Extrahepatic effects of nucleoside and nucleotide analogues in
chronic hepatitis B treatment. J Gastroenterol Hepatol. 29:428–434.
2014.PubMed/NCBI View Article : Google Scholar
|
